Dr. Daniel E. Spratt, M.D.
Radiation Oncology (Radiation Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Vanderbilt University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 148
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Vanderbilt University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Radiation Oncology Physician primary
OH license 35.141981 · MI license 4301106825 · SC license LL 32666
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uh Cleveland Medical Center Cleveland, OH
Medical groups
- University Hospitals Medical Group Inc (2,294 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 148
- Services billed
- 681
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Design and construction of complex radiation treatment device | 98 | 35 |
| Calculation of radiation therapy dose | 74 | 29 |
| Ct guidance for insertion of radiation therapy fields | 73 | 39 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
| Complex radiation therapy planning | 27 | 25 |
| 3d radiation therapy planning | 25 | 25 |
| Management of cranial lesion surgery using radiation over multiple sessions | 17 | 17 |
| Obtaining data needed to develop the optimal radiation treatment, 1 treatment area | 14 | 13 |
| Obtaining data needed to develop the optimal radiation treatment, 3 or more treatment areas or any number of treatment areas where special treatment is involved | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $9,495 in total to this clinician.
| AstraZeneca UK Limited | $3,640 |
|---|---|
| Novartis Pharmaceuticals Corporation | $2,800 |
| Janssen Biotech, Inc. | $1,725 |
| Boston Scientific Corporation | $1,300 |
| Siemens Medical Solutions USA, Inc. | $30.38 |
| Consulting Fee | $8,165 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,300 |
| Food and Beverage | $30.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Jun 26, 2025 | Consulting Fee | $2,800 |
| AstraZeneca UK Limited Apr 15, 2025 | Consulting Fee | $2,275 |
| Janssen Biotech, Inc. Oct 29, 2025 | Consulting Fee ERLEADA · Oncology | $1,725 |
| AstraZeneca UK Limited Jan 20, 2025 | Consulting Fee | $1,365 |
| Boston Scientific Corporation Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) SpaceOAR System · Space OAR_URO | $650 |
| Boston Scientific Corporation Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) SpaceOAR System · Space OAR_URO | $650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $269,112 in research payments for these studies, mostly to the institutions running them.
- A Phase II Double Blinded Placebo Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
Janssen Research & Development, LLC - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.